Amundi Asset Management US’s Nektar Therapeutics NKTR Stock Holding History

Amundi Asset Management US’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-15	Closed	-$4K	–	1553
2020 Q3	$4K	Hold	15	–	–	﹤0.01%	1580
2020 Q2	$5K	Buy	+15	New	+$4.68K	﹤0.01%	1590
2019 Q4	–	Sell	-4,098	Closed	-$1.12M	–	1649
2019 Q3	$1.12M	Sell	4,098 -676	-14%	-$248K	﹤0.01%	1213
2019 Q2	$2.55M	Sell	4,774 -1,825	-28%	-$915K	﹤0.01%	1093
2019 Q1	$3.33M	Sell	6,599 -12,579	-66%	-$7.45M	﹤0.01%	996
2018 Q4	$9.46K	Sell	19,178 -2	-0%	-$1.21K	0.01%	678
2018 Q3	$17.5M	Buy	19,180 +411	+2%	+$351K	0.02%	579
2018 Q2	$13.7M	Buy	18,769 +7,257	+63%	+$8.37M	0.02%	631
2018 Q1	$18.4M	Sell	11,512 -1,095	-9%	-$1.41M	0.03%	514
2017 Q4	$11.3M	Buy	+12,607	New	+$7.46M	0.02%	648

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Amundi Asset Management US's NKTR Position: Q4 2020 in Review

Amundi Asset Management US sold out of Nektar Therapeutics (NKTR) in Q4 2020, closing a stake of 15 shares — an estimated $4K sold.

Amundi Asset Management US first reported a position in NKTR in Q4 2017 and held it in 10 quarters. The position peaked at $18.4M in Q1 2018. 246 funds tracked by Wall St. Rank hold NKTR as of Q4 2020.

Amundi Asset Management US reported no remaining Nektar Therapeutics position as of Q4 2020 after selling out during the quarter.
Amundi Asset Management US sold 15 Nektar Therapeutics shares in Q4 2020, an estimated $4K.
Amundi Asset Management US first reported a position in Nektar Therapeutics in Q4 2017 and held it in 10 quarters.
Amundi Asset Management US's Nektar Therapeutics position peaked at $18.4M in Q1 2018.
246 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2020.

Based on Amundi Asset Management US's 13F filing for Q4 2020, filed 16 Feb 2021.